These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22123099)

  • 1. The economics of sepsis.
    Chalupka AN; Talmor D
    Crit Care Clin; 2012 Jan; 28(1):57-76, vi. PubMed ID: 22123099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economics and outcome in the intensive care unit.
    Pittoni GM; Scatto A
    Curr Opin Anaesthesiol; 2009 Apr; 22(2):232-6. PubMed ID: 19390250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The costs and cost-effectiveness of an integrated sepsis treatment protocol.
    Talmor D; Greenberg D; Howell MD; Lisbon A; Novack V; Shapiro N
    Crit Care Med; 2008 Apr; 36(4):1168-74. PubMed ID: 18379243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy.
    Burchardi H; Schneider H
    Pharmacoeconomics; 2004; 22(12):793-813. PubMed ID: 15294012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simplified pharmacoeconomics of critical care and severe sepsis.
    Ernst FR; Levy H; Qualy RL
    J Intensive Care Med; 2007; 22(5):283-93. PubMed ID: 17895486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs?
    Shorr AF; Micek ST; Jackson WL; Kollef MH
    Crit Care Med; 2007 May; 35(5):1257-62. PubMed ID: 17414080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of drotrecogin alfa (activated).
    Tsitanidis J
    Crit Care Med; 2003 Sep; 31(9):2414-5; author reply 2415. PubMed ID: 14501983
    [No Abstract]   [Full Text] [Related]  

  • 8. The economic burden of sepsis in Austria.
    Schmid A; Schneider H
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):1023-4; author reply 1024. PubMed ID: 12635473
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia.
    Eber MR; Laxminarayan R; Perencevich EN; Malani A
    Arch Intern Med; 2010 Feb; 170(4):347-53. PubMed ID: 20177037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations.
    Balk RA
    Dis Mon; 2004 Apr; 50(4):168-213. PubMed ID: 15133467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The cost of sepsis].
    Moerer O; Burchardi H
    Anaesthesist; 2006 Jun; 55 Suppl 1():36-42. PubMed ID: 16685555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economic methods: cost-minimization, cost-effectiveness, cost-utility, and cost-benefit evaluations.
    Higgins AM; Harris AH
    Crit Care Clin; 2012 Jan; 28(1):11-24, v. PubMed ID: 22123096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The incidence and cost of severe sepsis in intensive care units].
    Csomós A; Hoffer G; Fülesdi B; Ludwig E
    Orv Hetil; 2005 Jul; 146(29):1543-7. PubMed ID: 16136776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burden of illness imposed by severe sepsis in Switzerland.
    Schmid A; Pugin J; Chevrolet JC; Marsch S; Ludwig S; Stocker R; Finnern H
    Swiss Med Wkly; 2004 Feb; 134(7-8):97-102. PubMed ID: 15106026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical imperative versus economic consequence: exploring the cost burden and opportunities in the care of patients with sepsis.
    Merritt CL
    Nurs Adm Q; 2011; 35(1):61-7. PubMed ID: 21157265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation in critical care medicine.
    Cox HL; Laupland KB; Manns BJ
    J Crit Care; 2006 Jun; 21(2):117-24. PubMed ID: 16769454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden of illness imposed by severe sepsis in Austria.
    Schmid A; Schneider H; Adlof A; Smolle KH; Edelmann G; Sporn P; Frass M; Sumann G; Koller W; Schobersberger W
    Wien Klin Wochenschr; 2002 Aug; 114(15-16):697-701. PubMed ID: 12602114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drotrecogin alfa (activated; Xigris): an effective and cost-efficient treatment for severe sepsis.
    Doig CJ; Zygun DA; Delaney A; Manns BJ
    Expert Rev Pharmacoecon Outcomes Res; 2004 Feb; 4(1):15-26. PubMed ID: 19807332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost evaluation of patients with severe sepsis in intensive care units.
    Piacevoli Q; Palazzo F; Azzeri F
    Minerva Anestesiol; 2004 Jun; 70(6):453-71. PubMed ID: 15235553
    [No Abstract]   [Full Text] [Related]  

  • 20. [Calculation of costs per inpatient day in an intensive care unit].
    Alvear V S; Canteros J; Rodríguez P
    Rev Med Chil; 2010 May; 138(5):558-66. PubMed ID: 20668810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.